

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	8
-------	---	----	---

Complete if Known

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Art Unit	1644
Examiner Name	Z. SKELDING
Attorney Docket Number	1422-0709PUS1

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country ^a Code	Number/Kind Code (if known) ^b				
	5	WO	00/09168-A1	02-24-2000			
	6	WO	01/62895-A2	08-30-2001			
	7	WO	03/080817 - A1	02-10-2003			
	8	EP	0409655-A2	01-23-1991			
	9	EP	1424387 - A1	06-02-2004			
	10	EP	1666589 - A1	06-07-2006			

Examiner
SignatureDate
Considered

* **EXAMINER:** Include only if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation design number (optional). 2. See Kind Codes of USPTO patent Documents, at www.uspto.gov or MPEP 201.04. 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document and the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public: which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.**

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786.9199) and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Art Unit	1644
Examiner Name	Z. SKELDING
Attorney Docket Number	1422-0709PUS1

Sheet 4 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	20	"Animal Cell Culture: A Practical Approach", Edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C., 1986, pp. 26-41	<input type="checkbox"/>
	21	ANIMAL CELL CULTURE METHODS, edited by R. Freshney, Moscow, "Mir", 1989, pages 44, 53, 77 (the original English "Animal Cell Culture - A Practical Approach"), edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C.	<input type="checkbox"/>
	22	BENIGNI, Fabio et al.; Phenotype and Homing of CD4 Tumor-Specific T Cells is Modulated by Tumor Bulk; The Journal of Immunology; 2005, 175, pp. 739-748.	<input type="checkbox"/>
	23	DARDALHON et al., "Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector," Blood, Vol. 96, No. 3, 2000, pp. 885-893.	<input type="checkbox"/>
	24	FUNARO et al., "Stimulation of T Cells via CD44 Requires Leukocyte-Function-Associated Antigen Interactions and Interleukin-2 Production", Human Immunology, Vol. 40, 1994, pps. 267-278	<input type="checkbox"/>
	25	GATTINONI et al., "Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells," J. Clin. Invest., Vol. 115, No. 6, 2005, pp. 1616-1626.	<input type="checkbox"/>
	26	HALVORSON et al., "alpha4 and alpha5 integrins costimulate the CD3-dependent proliferation of fetal thymocytes," Cell. Immunol., Vol. 189, No. 1, 1998, pp. 1-9.	<input type="checkbox"/>
	27	HIBINO et al., "Tenascin Suppresses CD3-Mediated T Cell Activation", Biochemical and Biophysical Research Communications, Vol. 250, 1998, pp. 119-124.	<input type="checkbox"/>
	28	IDENO et al., "RetroNectin@ Kumiawaseta T Saibo Kakudai Baiyo (II): Kakudai Baiyo sareta T Saibo Shudan wa NaiveT-yo Saibo no Hiritsu ga Takaku, Takai Kogen Nishikino o Hakki," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330.	<input type="checkbox"/>
	29	IDENO et al., "Soshikital Human Fibronectin Fragment Shigeki ni yoru Kasseika CTL no Tairyo Expansion-ho," Dai 62 Kai Annual Meeting of the Japan Cancer Association Kiji, 2003, pp. 175.	<input type="checkbox"/>

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22315-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22315-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Art Unit	1644
Examiner Name	Z. SKELDING
Attorney Docket Number	1422-0709PUS1

Sheet	5	of	8
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	30	International Search Report in International Application No. PCT/JP02/08298 mailed December 3, 2002	<input type="checkbox"/>
	31	JPO International Search Report, Appl. No. PCT/JP2006/315881, October 10, 2006	<input type="checkbox"/>
	32	JPO International Search Report, Appl. No. PCT/JP2006/319105, January 9, 2007	<input type="checkbox"/>
	33	Kim YOUNG-JUNE et al., "4-1BB Costimulation Promotes Human T Cell Adhesion to Fibronectin", Cellular Immunology 192, 13-23 (1999)	<input type="checkbox"/>
	34	KOBERDA et al., "Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., Vol. 119, 1993, pp. 131-136.	<input type="checkbox"/>
	35	MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 1133-1148.	<input type="checkbox"/>
	36	MIZAMO, "Bulk Culture of Human Lymphocytes", Cell Technology, 1995, 14/2, 223-227.	<input type="checkbox"/>
	37	MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988.	<input type="checkbox"/>
	38	MURAKI et al., "Retronection® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Antelka shi, NaiveT-yo Saibo ga Kohritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330.	<input type="checkbox"/>
	39	Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English translation.	<input type="checkbox"/>

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with need communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9198 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 8

Complete if Known

Application Number 10/568,745
Filing Date 02-21-06
First Named Inventor Mitsuko Ideno
Art Unit 1644
Examiner Name Z. SKELDING
Attorney Docket Number 1422-0709PUS1

NON PATENT LITERATURE DOCUMENTS

Examiner Initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	40	Office Action in Chinese Application No. 200480024172.7 mailed November 30, 2007, including English translation.	<input type="checkbox"/>
	41	RAO, W. H. et al, "Potent Costimulation of Effector T Lymphocytes by Human Collagen Type I," J Immunol, 2000, vol. 165, pp. 4935-4940	<input type="checkbox"/>
	42	Retronectin, 2010, Takara Bio, Inc., http://catalog.takara-bio.co.jp/en/PDFFiles/T100A_B_e.pdf , p.1-8	<input type="checkbox"/>
	43	SAGAWA et al., "Ko-CD3 Kotal to RetroNectin??o Kumiawaseru Koto ni yoru LAK Saibo Inyu Ryoho no Kairyo," Dai 62 Kai Annual Meeting of the Japan Cancer Association Kiji," 2003, pp. 438.	<input type="checkbox"/>
	44	SEKINE, "Expansion of Lymphocytes by Culture with Immobilized Anti-CD3 Monoclonal Antibody and Interleukin-2 for Use in Adoptive Immunotherapy of Cancer Patients", Saibo Balyo (Cell Culture), Vol. 17, No. 6, 1991, pp. 192-195.	<input type="checkbox"/>
	45	SHUQIN et al., "Induction of Allogenic Cytotoxic T Lymphocytes and Their Culture", Journal of South China Normal University (Natural Science Edition), No. 4, 1994, pp. 11-17 (including partial English language translation)	<input type="checkbox"/>
	46	SIMON, Markus M. et al., The outer surface lipoprotein A of Borrelia burgdorferi provides direct and indirect augmenting/co-stimulatory signals for the activation of CD4+ and CD8+ T cells", Immunol. Lett., 1995, Vol. 46, No. 3, pp. 137-142.	<input type="checkbox"/>
	47	STOHL et al., "Generation of Cytolytic Activity with Anti-CD3 Monoclonal Antibodies Involves Both IL-2-Independent and -Dependent Components", J. Immunol., Vol. 144, No. 10, May 15, 1990, pp. 3718-3725	<input type="checkbox"/>
	48	STURM, A., et al, "Dual Function of the Extracellular Matrix: Stimulatory for Cell Cycle Progression of Naive T Cells and Antiapoptotic for Tissue-Derived Memory T Cells," The Journal of Immunology, 2004, vol. 173, pp. 3889-3900	<input type="checkbox"/>
	49	Supplementary European Search Report issued by the EPO in corresponding European Application No. 06782667.7 on September 16, 2009.	<input type="checkbox"/>

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/568,745
				Filing Date	02-21-06
				First Named Inventor	Mitsuko Ideno
				Art Unit	1644
				Examiner Name	Z. SKELDING
Sheet	7	of	8	Attorney Docket Number	1422-0709PUS1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	50	TAKAYAMA et al., "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial", The Lancet, Vol. 356, 2000, pp. 802-807	<input type="checkbox"/>
	51	US Office Action for Application No. 10/344,534, dated November 6, 2009	<input type="checkbox"/>
	52	US Office Action for Application No. 10/344,534, mailed May 13, 2008	<input type="checkbox"/>
	53	US Office Action for Application No. 10/344,534, November 24, 2009	<input type="checkbox"/>
	54	US Office Action for Application No. 10/486,512, dated June 25, 2004	<input type="checkbox"/>
	55	US Office Action for Application No. 10/509,055, dated May 11, 2007	<input type="checkbox"/>
	56	US Office Action for Application No. 10/509,055, mailed February 10, 2011	<input type="checkbox"/>
	57	US Office Action, dated August 31, 2010, for US Application No. 11/990,443	<input type="checkbox"/>
	58	US Office Action, dated December 28, 2010, for US Application No. 11/992,661	<input type="checkbox"/>
	59	US Office Action, dated February 10, 2011, for US Application No. 10/509,055	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/568,745
Filing Date	02-21-06
First Named Inventor	Mitsuko Ideno
Art Unit	1644
Examiner Name	Z. SKELDING
Attorney Docket Number	1422-0709PUS1

Sheet	8	of	8
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	60	US Office Action, dated July 6, 2011, for US Application No. 10/509,055	<input type="checkbox"/>
	61	US Office Action, dated June 9, 2011, for US Application No. 11/992,661	<input type="checkbox"/>
	62	US Office Action, dated March 16, 2011, for US Application No. 11/990,443	<input type="checkbox"/>
	63	US Office Action, dated October 14, 2010, for US Application No. 11/992,661	<input type="checkbox"/>
	64	WHITESIDE et al., "Isolation of Human NK Cells and Generation of LAK Activity, Current Protocols in Immunology", 1996, Supp. 17, Unit 7.7, pages 7.7.1-7.7.11.	<input type="checkbox"/>
	65	WILLIAMS et al., "Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions," Letters to Nature, Vol. 352, 1991, pp. 438-441	<input type="checkbox"/>
	66	WILLS, M. R., et al, "Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response," The Journal of Immunology, 2002, vol. 168, pp. 5455-5464	<input type="checkbox"/>
	67	ZHOU et al., "Molecular Mechanisms Underlying Differential Contribution of CD28 Versus Non-CD28 Costimulatory Molecules to IL-2 Promoter Activation," The Journal of Immunology, Vol. 168, 2002, pp. 3847-3854	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner
Signature

/Zachary Skelding/

Date
Considered

08/30/2011

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./